user

December 13, 2021

How to freeze-dry a potential COVID-19 vaccine

BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the microbe responsible for the coronavirus disease 2019 (COVID-19), through the development of a thermostable recombinant nanoparticle vaccine.
December 13, 2021
Coronavirus cells in microscopic view. Virus

POP Biotechnologies announces formation of joint venture, EUPOP Life Sciences, in collaboration with South Korean collaborator, Eubiologics, Co., Ltd.

POP Biotechnologies announces formation of joint venture, EUPOP Life Sciences, in collaboration with South Korean collaborator, Eubiologics, Co., Ltd. POP Biotechnologies (POP BIO) is pleased to […]
October 8, 2021

POP BIO awarded $599,981 Phase 1 SBIR Award to Develop Thermostable COVID-19 Vaccine

BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the microbe responsible for the coronavirus disease 2019 (COVID-19), through the development of a thermostable recombinant nanoparticle vaccine.
March 10, 2021
By JUSTIN WEISS March 3, 2021 | 10:18pm EST A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South […]
February 23, 2021

COVID-19 vaccine developed by UB startup approved for human trials

EuCorVac-19, a next-generation particle-based COVID-19 vaccine incorporating POP BIO's SNAP technology has gained regulatory approval for Phase I/II studies
January 16, 2021

EuCorVac-19 gains regulatory approval for Phase I / II clinical studies

SNAP-based EuBiologics EuCorVac-19 gains regulatory approval for Phase I/II trials in Korea EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a […]
July 16, 2020

POP BIO announces $3M equity investment and JV with Eubiologics for the RSV vaccine development

POP BIO announces $3M investment and JV formation with Eubiologics for the development of an RSV vaccine POP Biotechnologies, Inc. (POP BIO), a preclinical stage biotechnology […]
July 16, 2020

POP BIO awarded $599,897 NIH contract for HIV vaccine development with Scripps Research

POP Biotechnologies awarded $599,897 NIH contract for HIV vaccine development in collaboration with Scripps Research BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,897, […]
April 6, 2020

POP Biotechnologies awarded $399,917 NIH-NCI Phase I STTR in collaboration with Roswell Park

POP Biotechnologies awarded $399,917 NIH-NCI Phase I STTR in collaboration with Roswell Park BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $399,917 Phase I […]